Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
Fluticasone/salmeterol (FPS) showed no clear difference in adverse events—'serious' Duration of two years1 compared with placebo (low certainty).
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).
Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).
Reslizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).